Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02936505
Other study ID # Version 8.0
Secondary ID 154-162015-00413
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 12, 2016
Est. completion date October 30, 2026

Study information

Verified date April 2023
Source Vastra Gotaland Region
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A controlled randomized, open-label, multi-centre study evaluating if an immunosuppressive protocol, based on ATG-induction, once daily tacrolimus-dose (Advagraf®), mycophenolate mofetil and corticosteroid reduces the incidence of chronic lung allograft dysfunction (CLAD) after lung transplantation, in comparison with a standard cyclosporin-based protocol.


Description:

Study purpose: To evaluate whether the use of a once-daily tacrolimus-dose regimen (Advagraf®), based on anti-thymocyte globulin (Thymoglobulin®) induction, mycophenolate mofetil (MMF) and corticosteroids, reduces the cumulative incidence of CLAD after de novo lung transplantation at 36 months, in comparison with a twice-daily cyclosporin-based protocol, otherwise identical between groups.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Read more »

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen
Finland Helsinki University Hospital Helsinki
Norway Oslo University Hospital Oslo
Sweden Sahlgrenska Univ Hospital Göteborg
Sweden Skåne University Hospital Lund

Sponsors (5)

Lead Sponsor Collaborator
Vastra Gotaland Region Copenhagen University Hospital, Denmark, Helsinki University Central Hospital, Oslo University Hospital, Skane University Hospital

Countries where clinical trial is conducted

Denmark,  Finland,  Norway,  Sweden, 

References & Publications (1)

Dellgren G, Lund TK, Raivio P, Leuckfeld I, Svahn J, Magnusson J, Riise GC. Design and Rationale of a Scandinavian Multicenter Randomized Study Evaluating if Once-Daily Tacrolimus Versus Twice-Daily Cyclosporine Reduces the 3-year Incidence of Chronic Lung Allograft Dysfunction After Lung Transplantation (ScanCLAD Study). Adv Ther. 2020 Mar;37(3):1260-1275. doi: 10.1007/s12325-020-01224-1. Epub 2020 Jan 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with incidence of CLAD The cumulative incidence of CLAD (including both BOS and RAS, as defined in the Appendix II) after lung transplantation. 36 months is primary outcome
Primary Number of patients with incidence of CLAD The cumulative incidence of CLAD (including both BOS and RAS, as defined by the Appendix II) at 48 months after lung transplantation. 48 months is outcome for the continuation study
Primary Number of patients with incidence of CLAD The cumulative incidence of CLAD (including both BOS and RAS, as defined by the Appendix II) at 60 months after lung transplantation. 60 months is outcome for continuation study
Primary Number of patients with incidence of CLAD The cumulative incidence of CLAD (including both BOS and RAS, as defined by the Appendix II) at 72 months after lung transplantation. 72 months is outcome for continuation study
Secondary Glomerular Filtration Rate Renal function evaluated by measured glomerular filtration rate 3 months
Secondary Primary graft dysfunction Cumulative incidence of primary graft dysfunction 72 hours
Secondary Composite measure of freedom from AR, CLAD, graft and patient survival Composite measure of freedom from first event of AR, CLAD, graft survival, and patient survival 12 months
Secondary Composite measure of freedom from AR, CLAD, graft and patient survival Composite measure of freedom from first event of AR, CLAD, graft survival, and patient 24 months
Secondary Composite measure of freedom from AR, CLAD, graft and patient survival Composite measure of freedom from first event of AR, CLAD, graft survival, and patient 36 months
Secondary Incidence of primary graft dysfunction cumulative incidence of primary graft dysfunction 72 hours
Secondary Patient survival Patient survival 1 year
Secondary Patient survival Patient survival 3 year
Secondary Cumulative incidence of acute allograft rejection and CLAD The cumulative incidence of acute allograft rejection (AR) and CLAD. - Determined by clinical criteria, computed tomography (CT) and trans bronchial lung biopsy with broncho-alveolar lavage (BAL). - Number of rejections (cellular and antibody mediated), stratified by biopsy and non-biopsy verified rejections. 6 months
Secondary Cumulative incidence of acute allograft rejection and CLAD The cumulative incidence of acute allograft rejection (AR) and CLAD. - Determined by clinical criteria, computed tomography (CT) and trans bronchial lung biopsy with broncho-alveolar lavage (BAL). - Number of rejections (cellular and antibody mediated), stratified by biopsy and non-biopsy verified rejections. 1 year
Secondary Cumulative incidence of acute allograft rejection and CLAD The cumulative incidence of acute allograft rejection (AR) and CLAD. - Determined by clinical criteria, computed tomography (CT) and trans bronchial lung biopsy with broncho-alveolar lavage (BAL). - Number of rejections (cellular and antibody mediated), stratified by biopsy and non-biopsy verified rejections. 3 year
Secondary Cumulative incidence of BOS and RAS The cumulative incidence of BOS and RAS 6 months
Secondary Cumulative incidence of BOS and RAS The cumulative incidence of BOS and RAS 1 year
Secondary Cumulative incidence of BOS and RAS The cumulative incidence of BOS and RAS 3 year
Secondary Development of donor specific antibodies Development of donor specific antibodies (DSA) according to specific protocol. 12 months
Secondary Development of donor specific antibodies Development of donor specific antibodies (DSA) according to specific protocol. 24 months
Secondary Development of donor specific antibodies Development of donor specific antibodies (DSA) according to specific protocol. 36 months
Secondary Renal function mGFR Renal function evaluated by measured glomerular filtration rate (mGFR), by Iohexol or Cr-EDTA clearance. 12 months
Secondary Renal function mGFR Renal function evaluated by measured glomerular filtration rate (mGFR), by Iohexol or Cr-EDTA clearance. 24 months
Secondary Renal function mGFR Renal function evaluated by measured glomerular filtration rate (mGFR), by Iohexol or Cr-EDTA clearance. 36 months
Secondary Renal function cGFR Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas. 3 months
Secondary Renal function cGFR Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas. 12 months
Secondary Renal function cGFR Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas. 24 months
Secondary Renal function cGFR Renal function evaluated by calculated glomerular filtration rate (cGFR), by three different Formulas. 36 months
Secondary Post Transplantation Diabetes Mellitus The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below. Cumulative incidence of
=2 Fasting Plasma Glucose (FPG) =7,0 mmol/L = 30 consecutive days apart. Oral hypoglycaemic treatment =30 consecutive days. Insulin =30 consecutive days. HgbA1c =6.5% (according to American Diabetes Association - ADA)Symptoms of Diabetes and Random Plasma Glucose (RPG) = 11.1 mmol/L.
2-hour Plasma Glucose (2-hPG) = 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.
6 months
Secondary Post Transplantation Diabetes Mellitus The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below. Cumulative incidence of
=2 Fasting Plasma Glucose (FPG) =7,0 mmol/L = 30 consecutive days apart. Oral hypoglycaemic treatment =30 consecutive days. Insulin =30 consecutive days. HgbA1c =6.5% (according to American Diabetes Association - ADA) Symptoms of Diabetes and Random Plasma Glucose (RPG) = 11.1 mmol/L. 2-hour Plasma Glucose (2-hPG) = 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.
12 months
Secondary Post Transplantation Diabetes Mellitus The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below. Cumulative incidence of
=2 Fasting Plasma Glucose (FPG) =7,0 mmol/L = 30 consecutive days apart. Oral hypoglycaemic treatment =30 consecutive days. Insulin =30 consecutive days. HgbA1c =6.5% (according to American Diabetes Association - ADA) Symptoms of Diabetes and Random Plasma Glucose (RPG) = 11.1 mmol/L. 2-hour Plasma Glucose (2-hPG) = 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.
24 months
Secondary Post Transplantation Diabetes Mellitus The cumulative incidence of Post Transplantation Diabetes Mellitus (PTDM) after transplantation as defined below -Cumulative incidence of:
=2 Fasting Plasma Glucose (FPG) =7,0 mmol/L = 30 consecutive days apart. Oral hypoglycaemic treatment =30 consecutive days. Insulin =30 consecutive days. HgbA1c =6.5% (according to American Diabetes Association - ADA)Symptoms of Diabetes and Random Plasma Glucose (RPG) = 11.1 mmol/L.
2-hour Plasma Glucose (2-hPG) = 11.1 mmol/L during an oral glucose tolerance test (OGTT). Baseline OGTT will be performed pre-transplant.
36 months
Secondary Antidiabetic medication Use of antidiabetic medication 6 months
Secondary Antidiabetic medication Use of antidiabetic medication 12 months
Secondary Antidiabetic medication Use of antidiabetic medication 24 months
Secondary Antidiabetic medication Use of antidiabetic medication 36 months
Secondary Antihypertensive and lipid lowering drugs Incidence and number of antihypertensive and lipid lowering drug 12 months
Secondary Antihypertensive and lipid lowering drugs Incidence and number of antihypertensive and lipid lowering drug 24 months
Secondary Antihypertensive and lipid lowering drugs Incidence and number of antihypertensive and lipid lowering drug 36 months
Secondary Proteinuria Development and magnitude of proteinuria 12 months
Secondary Proteinuria Development and magnitude of proteinuria 24 months
Secondary Proteinuria Development and magnitude of proteinuria 36 months
Secondary Lipid profile Lipid profile (Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, TSH, T4, HbA1c) 12 months
Secondary Lipid profile Lipid profile (Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, TSH, T4, HbA1c) 24 months
Secondary Lipid profile Lipid profile (Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, TSH, T4, HbA1c) 36 months
Secondary Cytomegalovirus Incidence of Cytomegalovirus (CMV) that required treatment (CMV-infection and CMV syndrome). 0-36 months
Secondary Malignancy stratified by post-transplant lymphoproliferative disorder (PTLD) and all other cancers. Cumulative incidence of malignancy stratified by post-transplant lymphoproliferative disorder (PTLD) and all other cancers. 36 months
Secondary Safety and tolerability Safety and tolerability 0-36 months
Secondary Quality of life assessed by EQ5D Questionnaire Quality of life, the relative difference over time will be investigated after LTx, where 5 questions are raised and answer is between 11111 (no problems) and 33333 (extreme problems in all dimensions) 12 months
Secondary Quality of life assessed by St Georges Respiratory Questionnaire (SGRQ) Quality of life, the relative difference over time will be investigated after LTx. The SGRQ total score ranges from 0 to 100 where 100 indicates the worst quality of life. 12 months
Secondary Quality of life, assessed by EQ5D Questionnaire Quality of life, the relative difference over time will be investigated after LTx, where 5 questions are raised and answer is between 11111 (no problems) and 33333 (extreme problems in all dimensions). 24 months
Secondary Quality of life, assessed by St Georges Respiratory Questionnaire (SGRQ) Quality of life, the relative difference over time will be investigated after LTx. The SGRQ total score ranges from 0 to 100 where 100 indicates the worst quality of life. 24 months
Secondary Quality of life, assessed by EQ5D Questionnaire (SGRQ) Quality of life, the relative difference over time will be investigated after LTx, where 5 questions are raised and answer is between 11111 (no problems) and 33333 (extreme problems in all dimensions). 36 months
Secondary Quality of life, assessed by St Georges Respiratory Questionnaire (SGRQ) Quality of life, the relative difference over time will be investigated after LTx. The SGRQ total score ranges from 0 to 100 where 100 indicates the worst quality of life. 36 months
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 0h after administration, of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 1h after administration of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 2h after administration of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 3h after administration of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 4h after administration of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 6h after administration of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics (from whole blood concentrations from at 8h after administration and of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics (from whole blood concentrations from at 10h after administration and of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics (from whole blood concentrations at 12h after administration and of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 23h after administration and of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics from whole blood concentrations at 24h after administration and of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics, of the Tacrolimus drug in patients in the CF sub group population Define the pharmacokinetics as an AUC construction, of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. week 4
Secondary Pharmacokinetics of the Tacrolimus drug in patients in the CF sub group Define the pharmacokinetics as an AUC construction, of Tacrolimus in non-CF patients (n=12) and all included CF patients (n=15-20) undergoing primary lung transplantation (LTx) treated with an Advagraf® based-immunosuppression. 6 months
Secondary Immunological equipotency of tacrolimus and cyclosporine A Immunological equipotency of tacrolimus once daily (OD) and cyclosporine A twice daily (BiD) in vivo and in vitro, according to separate protocol. 0-36 months
Secondary Occurrence of treatment failures Occurrence of treatment failures up to or at 36 months; defined as a composite endpoint of graft loss, death, loss to follow up or discontinuation due to lack of efficacy or toxicity (at least one condition must be present). 0-36 months
Secondary Recovery of right heart function Recovery of right heart function irrespective of diagnosis in patients with pulmonary arterial hypertension (PAH, categories 1-5 according to WHO 1-5). 0-36 months
See also
  Status Clinical Trial Phase
Completed NCT02581111 - Naloxone for Optimizing Hypoxemia Of Lung Donors Phase 2/Phase 3
Recruiting NCT02177916 - Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation N/A
Not yet recruiting NCT01394835 - Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients Phase 2
Not yet recruiting NCT01162148 - Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation N/A
Completed NCT01204970 - Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients N/A
Active, not recruiting NCT00980967 - Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study N/A
Completed NCT00531921 - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival N/A
Recruiting NCT00163696 - Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease N/A
Completed NCT00177684 - Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Phase 3
Completed NCT00163891 - Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients N/A
Completed NCT03668483 - Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx N/A
Not yet recruiting NCT02855372 - Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT) N/A
Completed NCT01212406 - Vitamin D in Bronchiolitis Obliterans Syndrome Phase 4
Completed NCT01211509 - Montelukast in Bronchiolitis Obliterans Syndrome Phase 4
Not yet recruiting NCT00808600 - Empowerment of Lung and Heart-lung Transplant Patients N/A
Completed NCT00553397 - Live Lung Donor Retrospective Study N/A
Completed NCT00402805 - Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Phase 4
Terminated NCT00235651 - Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients Phase 3
Completed NCT00701922 - Surveillance Study of Viral Infections Following Lung Transplantation N/A
Recruiting NCT03798860 - Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

External Links